Answers are grounded in this paper and cite their sources.
Narrative review reveals individualized target and procedural selection strategies in movement disorders, highlighting tailored multidisciplinary evaluation over universal algorithms.
Background Surgical treatment of movement disorders has expanded substantially with advances in deep brain stimulation (DBS), magnetic resonance-guided focused ultrasound (MRgFUS), stereotactic targeting, and emerging neuromodulation technologies. However, selection among these approaches remains complex because treatment decisions depend on disease phenotype, symptom distribution, medication responsiveness, cognitive and psychiatric status, procedural risk, treatment goals, and patient preferences. Existing literature frequently addresses individual disorders or procedures, whereas an integrated framework for contemporary surgical decision-making across major movement disorders is less consistently presented. Objective To synthesize clinically relevant evidence regarding patient selection, target selection, procedure selection, and emerging technologies in functional neurosurgery for Parkinson's disease, essential tremor, dystonia, Tourette syndrome, Huntington disease, and selected related movement disorders. Methods A narrative review of the contemporary literature was conducted using PubMed, Scopus, and Google Scholar. The search strategy incorporated controlled vocabulary and free-text terms relating to movement disorders, Parkinson's disease, essential tremor, dystonia, Tourette syndrome, deep brain stimulation, MR-guided focused ultrasound, lesioning procedures, and functional neurosurgery. Randomized controlled trials, prospective and retrospective clinical studies, systematic reviews, meta-analyses, consensus statements, and relevant contemporary technology studies were considered. Evidence was interpreted according to study design, consistency of findings, clinical applicability, and relevance to surgical decision-making. Because this was a narrative review, no formal meta-analysis or quantitative evidence grading was performed. Results Contemporary surgical decision-making is primarily determined by diagnostic certainty, clinically meaningful disability despite optimized medical therapy, cognitive and psychiatric suitability, symptom phenotype, and individualized treatment goals. In Parkinson's disease, both subthalamic nucleus (STN) and globus pallidus internus (GPi) stimulation provide substantial motor benefit in appropriately selected patients, while target selection should incorporate medication-reduction goals, dyskinesia burden, cognitive and psychiatric vulnerability, axial symptoms, and medication requirements. For essential tremor, ventral intermediate nucleus (VIM) DBS remains an established option, particularly when bilateral or adjustable treatment is required, while MRgFUS provides an incisionless lesioning alternative for selected patients, with unilateral treatment established and staged bilateral treatment emerging for selected patients with bilateral essential tremor. Dystonia outcomes vary substantially according to etiology, distribution, disease duration, and fixed musculoskeletal changes, with GPi-DBS remaining the most established target for generalized and segmental forms. DBS and MRgFUS should not be considered interchangeable procedures; their relative advantages and limitations differ with respect to adjustability, laterality, hardware requirements, adverse effects, and long-term management. Emerging technologies—including directional stimulation, adaptive DBS, connectomic targeting, robotic stereotaxy, remote programming, wearable monitoring, and artificial intelligence—remain at different stages of clinical maturity and should be distinguished from established standard-of-care interventions. Conclusions Contemporary movement-disorder surgery requires individualized, multidisciplinary decision-making rather than a universal target- or procedure-based algorithm. The available evidence supports disease-specific assessment of medical refractoriness, symptom phenotype, cognition, psychiatric status, procedural risk, and patient goals before selecting a target or modality. DBS remains an established and adjustable neuromodulatory treatment for several movement disorders, whereas MRgFUS provides a complementary lesioning option for appropriately selected indications. Emerging technologies may further individualize treatment, but their clinical adoption should remain proportionate to the strength and maturity of available evidence.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: